Based on the Minerva Neurosciences Inc stock forecast from 1 analysts, the average analyst target price for Minerva Neurosciences Inc is USD 5.00 over the next 12 months. Minerva Neurosciences Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Minerva Neurosciences Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Minerva Neurosciences Inc’s stock price was USD 1.37. Minerva Neurosciences Inc’s stock price has changed by -24.31% over the past week, -17.47% over the past month and -46.06% over the last year.
No recent analyst target price found for Minerva Neurosciences Inc
No recent average analyst rating found for Minerva Neurosciences Inc
Company Overview Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, submitted a New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. Read Less
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone (MIN-101) for the treatment o...Read More
Frequently Asked Questions About Minerva Neurosciences Inc (NERV) Stock
Based on ratings from 1 analysts Minerva Neurosciences Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on NERV's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for NERV is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
NERV stock's Price/Earning ratio is 9.47.
Our analysis grades NERV stock's Price / Earning ratio at F. This means that NERV stock's Price/Earning ratio is above 55.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this NERV may be a overvalued for its sector.
The last closing price of NERV's stock was USD 1.37.
The most recent market capitalization for NERV is USD 0.01B.
Based on targets from 1 analysts, the average taret price for NERV is projected at USD 5.00 over the next 12 months.
This means that NERV's stock price may go up by +264.96% over the next 12 months.
We can't find any ETFs which contains Minerva Neurosciences Inc's stock.
As per our most recent records Minerva Neurosciences Inc has 8 Employees.
Minerva Neurosciences Inc's registered address is 1500 District Avenue, Burlington, MA, United States, 01803.
You can get more information about it from Minerva Neurosciences Inc's website at https://www.minervaneurosciences.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Minerva Neurosciences Inc (NERV) Stock
Based on ratings from 1 analysts Minerva Neurosciences Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on NERV's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for NERV is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
NERV stock's Price/Earning ratio is 9.47.
Our analysis grades NERV stock's Price / Earning ratio at F. This means that NERV stock's Price/Earning ratio is above 55.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this NERV may be a overvalued for its sector.
The last closing price of NERV's stock was USD 1.37.
The most recent market capitalization for NERV is USD 0.01B.
Based on targets from 1 analysts, the average taret price for NERV is projected at USD 5.00 over the next 12 months.
This means that NERV's stock price may go up by +264.96% over the next 12 months.
We can't find any ETFs which contains Minerva Neurosciences Inc's stock.
As per our most recent records Minerva Neurosciences Inc has 8 Employees.
Minerva Neurosciences Inc's registered address is 1500 District Avenue, Burlington, MA, United States, 01803.
You can get more information about it from Minerva Neurosciences Inc's website at https://www.minervaneurosciences.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for NERV !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
